{"id":"W4406775014","doi":"10.1002/ajh.27539","title":"Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study","year":2025,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Chugai Pharmaceutical; Genentech; Grifols; AOP Orphan; Novo Nordisk; Argenx; Regeneron Pharmaceuticals; Bristol-Myers Squibb; CSL Behring; Celgene; CTI Biopharma; Swedish Orphan Biovitrum; Apellis Pharmaceuticals; BioCryst; Alnylam Pharmaceuticals; Sanofi; Alexion Pharmaceuticals; Amgen; Pfizer","keywords":"Immune thrombocytopenia; Bruton's tyrosine kinase; Medicine; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Immunology; Gastroenterology; Antibody; Receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00214653,0.001343272,0.001535125,0.000375592,0.0003810858,0.0009934022,0.0005635236,0.001086026,0.003141768],"category_scores_gemma":[0.0008253283,0.000443591,0.001295566,0.0003442389,0.0005054717,0.0006500643,0.0002680636,0.002408934,0.0008610611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006567633,"about_ca_system_score_gemma":0.0009790498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008724993,"about_ca_topic_score_gemma":0.001167079,"domain_scores_codex":[0.9994154,0.000312661,0.00003267294,0.00007183609,0.00006861305,0.00009890404],"domain_scores_gemma":[0.9994624,0.00008914683,0.0001351101,0.00005179172,0.00004989332,0.0002115857],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.599368,0.08334192,0.01735825,0.001190103,0.002838364,0.0005824481,0.0003818651,0.003551767,0.09856459,0.000316468,0.01412634,0.17838],"study_design_scores_gemma":[0.4613246,0.4603688,0.05978975,0.0001020263,0.001280388,0.000720073,0.00008376323,0.002234119,0.007399439,0.0002433107,0.006378429,0.00007524192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873874,0.005212063,0.0007020214,0.0004907716,0.00007166753,0.001343391,0.002384112,0.00009807952,0.002310591],"genre_scores_gemma":[0.9856616,0.002902462,0.001293584,0.001210263,0.0001831416,0.001766242,0.004977891,0.00004438311,0.001960536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003141768,"threshold_uncertainty_score":0.01135206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01100729598929618,"score_gpt":0.3249805975566005,"score_spread":0.3139733015673044,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}